Summary of Quantum-Si Incorporated Q1 2026 Earnings Call

1Key Financial Results and Metrics:

Revenue: $258,000, primarily from Platinum instruments and consumables.

Gross Profit: $74,000, with a gross margin of 29%, influenced by a higher proportion of consumables sold.

Operating Expenses: GAAP operating expenses were $24.1 million, down from $25.6 million in Q1 2025. Adjusted operating expenses were $21.4 million, compared to $22.9 million in the prior year.

Cash Position: As of March 31, 2026, the company had $190.4 million in cash, cash equivalents, and marketable securities.

Outlook: Expected total revenue for 2026 is approximately $1 million, with adjusted operating expenses capped at $98 million.

2Strategic Updates and Business Highlights:

Proteus Development: Significant progress made, including successful sequencing on integrated Proteus instruments. The platform is expected to outperform the existing Platinum technology in terms of automation, throughput, and proteome coverage.

Market Preparation: Initiatives include a roadshow series to educate potential customers about Proteus and its capabilities. Early interest has been strong, particularly regarding applications in post-translational modifications (PTMs).

Customer Engagement: Positive feedback from early access customers using the Proteus prototype, indicating improvements in amino acid detection and read lengths compared to Platinum.

3Forward Guidance and Outlook:

2026 Focus: The year is viewed as a transition period, with expectations of modest revenue growth as customers await the Proteus launch.

Long-term Goals: Management believes Proteus will drive future revenue growth and profitability, with plans to maintain fiscal discipline while funding strategic initiatives.

Cash Runway: The current cash position is projected to support operations into 2028, allowing for flexibility in managing expenses post-Proteus launch.

4Bad News, Challenges, or Points of Concern:

Revenue Generation: Current revenue is low, reflecting a transition phase as customers delay purchases until the Proteus launch.

Operating Expense Management: While expenses have decreased, the company is still investing heavily in R&D, which could strain resources if revenue does not increase as anticipated.

Market Risks: The reliance on external partners for manufacturing and development could pose risks if there are delays or issues in scaling production.

5Notable Q&A Insights:

Customer Experience with Proteus: Enhanced capabilities in amino acid detection and longer read lengths are expected to improve customer applications significantly, particularly in complex protein mixtures and PTMs.

Volume Expectations: While it is difficult to predict exact volume increases when switching from Platinum to Proteus, management anticipates that Proteus will open up new applications and customer segments, potentially increasing utilization.

Early Access Program: The selection process for early access sites will focus on a mix of academic and commercial environments to gather diverse data and experiences.

Roadshow Feedback: Customers are excited about the potential of Proteus, especially for PTM analysis, and initial pricing feedback has been positive, with no significant pushback noted. Overall, Quantum-Si is in a critical transition phase as it prepares for the launch of its Proteus platform, with a focus on maintaining financial strength while driving customer engagement and market education.